CTIS2023-504376-21-00
Recruiting
Phase 1
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours
Peptomyc S.L.0 sites30 target enrollmentApril 21, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Peptomyc S.L.
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
Active, not recruiting
Phase 1
Safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantatio(Patients awaiting) kidney transplantationMedDRA version: 20.0Level: PTClassification code 10021425Term: Immune system disorderSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-004154-28-ESSanofi-Aventis Recherche & Développement42
Active, not recruiting
Phase 1
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerPancreatic Ductal AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001028-21-ESMedImmune, LLC204
Active, not recruiting
Phase 1
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerEUCTR2018-001028-21-NOMedImmune, LLC195